Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Apr 14, 2022 in Breast cancer | 0 comments

In a nutshell

This study compared the effectiveness and safety of trastuzumab emtansine (T-DM1; Kadcyla) plus pertuzumab (Perjeta) versus taxanes plus trastuzumab (Herceptin) plus pertuzumab (THP) in patients with high-risk HER2-positive (+) early breast cancer (BC) after previous treatment with anthracycline-based chemotherapy. The data showed that both regimens had similar effectiveness and the THP regimen remained the standard of care for these patients.

Some background

BC is classified into different subtypes depending on the presence or absence of certain receptors (proteins found on the surface of the cancer cells). HER2 (human epidermal growth factor receptor 2) is a protein that promotes the growth of some BC. This subtype of BC is called HER2-positive (HER2+) BC. There are many treatment options for early-stage HER2+ BC.

The standard care for advanced HER2+ BC is THP (taxanes + trastuzumab + pertuzumab). Trastuzumab and pertuzumab are targeted therapy drugs used to treat metastatic HER2+ BC. Trastuzumab and pertuzumab lock onto HER2 and inhibit its actions. Taxanes are chemotherapy drugs such as docetaxel (Taxotere) or paclitaxel (Taxol). Trastuzumab emtansine (T-DM1) is a drug like trastuzumab used in patients with BC that have high levels of HER2. This is a molecule that specifically targets cancer cells and reduces the side effects to normal cells.

It is not known whether T-DM1 plus pertuzumab or THP works better in patients with high-risk HER2+ early BC after previous treatment with anthracycline-based chemotherapy.

Methods & findings

This study involved 1846 women with high-risk HER2+ early BC. Patients were randomly assigned into 2 groups after previous treatment with anthracycline-based chemotherapy. Group 1 included 918 patients who received THP regimen. Group 2 included 928 patients who received T-DM1 plus pertuzumab. The average follow-up time was 57 months for group 1 and 57.1 months for group 2.

After 3 years, 94.2% of the patients in group 1 were alive without any signs or symptoms of cancer (disease-free) compared to 93.1% of the patients in group 2. This difference was not significant.

Overall, 88.4% of the patients in group 1 completed the treatment compared to 65% of the patients in group 2.

The rate of serious side effects was similar between the 2 groups (23.3% in group 1 vs 21.4% in group 2).

The bottom line

This study concluded that both regimens showed similar effectiveness. The authors suggested that the THP regimen should remain the standard of care for patients with high-risk HER2+ early BC.

The fine print

This study was sponsored by F. Hoffmann-La Roche Ltd and Genentech, the manufacturers of T-DM1.

Published By :

Journal of clinical oncology

Date :

Dec 10, 2021

Original Title :

Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study.

click here to get personalized updates